12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Gossamer Bio
Prelude Therapeutics, Inc.
ProMIS Neurosciences Inc.
Aldeyra Therapeutics, Inc.
Altimmune Inc

Gossamer Bio

GOSS

0.00

Prelude Therapeutics, Inc.

PRLD

0.00

ProMIS Neurosciences Inc.

PMN

0.00

Aldeyra Therapeutics, Inc.

ALDX

0.00

Altimmune Inc

ALT

0.00

Gainers

  • Gossamer Bio (NASDAQ:GOSS) shares moved upwards by 47.2% to $0.29 during Tuesday's pre-market session. The company's market cap stands at $97.4 million.
  • Prelude Therapeutics (NASDAQ:PRLD) shares moved upwards by 20.3% to $4.68. The market value of their outstanding shares is at $309.8 million.
  • ProMIS Neurosciences (NASDAQ:PMN) stock increased by 16.46% to $13.65. The company's market cap stands at $105.1 million.
  • Aldeyra Therapeutics (NASDAQ:ALDX) shares moved upwards by 11.04% to $1.76. The company's market cap stands at $95.6 million.
  • Altimmune (NASDAQ:ALT) stock rose 8.8% to $3.22. The market value of their outstanding shares is at $575.6 million.
  • IQVIA Holdings (NYSE:IQV) shares rose 8.76% to $231.9. The company's market cap stands at $35.5 billion. As per the news, the Q2 earnings report came out today.

Losers

  • Replimune Group (NASDAQ:REPL) shares fell 24.7% to $6.5 during Tuesday's pre-market session. The company's market cap stands at $724.4 million.
  • Nexalin Technology (NASDAQ:NXL) stock decreased by 16.29% to $0.37. The market value of their outstanding shares is at $9.7 million.
  • BiomX (AMEX:PHGE) shares decreased by 12.92% to $0.17. The market value of their outstanding shares is at $2.1 million.
  • Outlook Therapeutics (NASDAQ:OTLK) shares decreased by 11.92% to $0.94. The company's market cap stands at $158.2 million.
  • Autonomix Medical (NASDAQ:AMIX) shares fell 11.83% to $2.46. The company's market cap stands at $1.5 million.
  • China SXT Pharmaceuticals (NASDAQ:SXTC) shares decreased by 11.61% to $0.06. The company's market cap stands at $2.6 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.